340B Pricing, Penalty Alternatives Will Be Reassessed; Final Rule Delayed
This article was originally published in The Pink Sheet Daily
Pharma pushback pays off as HRSA requests additional public comment on key issues, including 340B ceiling prices and manufacturer civil monetary penalties.
You may also be interested in...
Final rule on 340B discounts also addresses how to handle pricing for new drugs.
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.